Pharmacokinetics and pharmacodynamics of topiramate.
In the treatment of children with epilepsy, the role of topiramate has been expanding gradually. The main factor that has contributed to this trend is the relatively large body of information that has accumulated on the clinical pharmacology of topiramate in children, including its broad-spectrum efficacy, pediatric pharmacokinetics, side-effect profile, and safety. It has also become increasingly apparent with time that topiramate, in contrast to other broad-spectrum antiepileptic drugs used in children, does not seem to be associated with a significant risk of any serious or life-threatening adverse effects. The present review summarizes the available evidence related to the clinical pharmacology of topiramate in children and provides an update on its known mechanisms of action. Finally, available experimental data on the neuroprotective effect of topiramate are reviewed because of their considerable clinical potential in the treatment of children and newborns.
Bourgeois
B F
BF
Division of Epilepsy and Clinical Neurology, Children's Hospital, Boston, MA 02115, USA. bourgeois_b@a1.tch.harvard.edu
D000293:Adolescent; D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015220:Calcium Channels / Q000378:metabolism; D002256:Carbonic Anhydrases / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000188:drug therapy*; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007608:Kainic Acid / Q000378:metabolism; D015222:Sodium Channels / Q000378:metabolism; D000077236:Topiramate; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000927:Anticonvulsants; D015220:Calcium Channels; D015222:Sodium Channels; D000077236:Topiramate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D002256:Carbonic Anhydrases; D007608:Kainic Acid